Clinical trials: Macular Pigment
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for they eye to adjust to low light.
- Trial name
- NCT03478878
- Testing
- Vitamin A Palmitate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Eye Institute (NEI)
Geographic Atrophy, Age-Related Macular Degeneration
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration.
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration, AMD
- Trial name
- NCT00306488
- Testing
- OT-551 antioxidant eye drop
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Retinal Diseases, Telangiectasis
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Idiopathic Parafoveal Telangiectasia (IPT) [also known as Idiopathic Perifoveal Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia (MacTel)] is a disorder of unknown etiology.
- Trial name
- HD-LIPT (NCT01205035)
- Testing
- ranibizumab 2.0mg
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Eye Center of Northern Colorado, P.C.
Vision, Entoptic
Macular Pigment and Glare Disability
The purpose of this study is: I. To measure MP optical density (MPOD) in two groups (experimental and placebo) of 50 subjects each (N = 100), during an Lutein + Zeaxanthin supplementation period of 12 months. II.
- Trial name
- MP-GD (NCT00909090)
- Testing
- 12 mg Lutein + Zeaxanthin
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Age Related Macular Degeneration
Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed…
- Trial name
- RIP (NCT01914159)
- Testing
- Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- University Hospital, Bonn
Age Related Macular Degeneration
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
The investigators hope to determine if "wet" AMD patients differ from patients with "dry" AMD or normal eyes in the production of anti-retinal pigment epithelium (anti-RPE) or anti-retinal antibody formation.
- Trial name
- Antibody (NCT00931489)
- Testing
- ranibizumab (Lucentis(R))
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Lawrence S. Morse, MD
Posterior Capsule Opacification, Retinal Degeneration
Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification
It has been hypothesized that potential effects of laser Nd: YAG laser posterior capsulotomy may affect macular pigment as well as choroidal thickness, macular thickness and anterior chamber parameters, so it was aimed to…
- Conditions
- Posterior Capsule Opacification, Retinal Degeneration, Retinal Detachment, Anterior Chamber Angle Congestion
- Trial name
- NCT03321253
- Testing
- Nd: YAG laser posterior capsulotomy
- Volunteers
- 38 people
- Sponsor
- Afyon Kocatepe University Hospital
AMD
Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for the eye to adjust to low light.
- Trial name
- NCT03478865
- Testing
- Vitamin A palmitate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Eye Institute (NEI)
Glaucoma
Macular Pigment and Visual Performance in Glaucoma Patients
The purpose of this study is to determine cross-sectional relationships between macular pigment optical density (MPOD) and visual performance in glaucoma.
- Trial name
- NCT03959592
- Testing
- Lutein, zeaxanthin and mesozeaxanthin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Felipe Medeiros, MD
Macular Degeneration, Wet Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
- Conditions
- Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases
- Trial name
- ARI2 (NCT02157077)
- Testing
- Aflibercept
- Where
- 9 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Age Related Macular Degeneration, Cognition Disorders
The Zeaxanthin and Visual Function Study
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
- Trial name
- ZVF (NCT00564902)
- Testing
- 3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Chrysantis, Inc.
Age-Related Macular Degeneration
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells.
- Trial name
- NCT02286089
- Testing
- OpRegen
- Where
- 7 sites in United States, Israel
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Age Related Macular Degeneration, Geographic Atrophy
Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)
The objective of this study is to compare Cirrus HD-OCT automated measurements of the illumination area under the retinal pigment epithelium (RPE) to expert manual measurements of areas of hypofluorescence typical of geographic…
- Trial name
- NCT01272076
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Carl Zeiss Meditec, Inc.
Age-related Macular Degeneration
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
This study is to investigate the protective effects of supplemental lutein and zeaxanthin on early age-related macular degeneration (AMD) patients in China.
- Trial name
- NCT01528605
- Testing
- low lutein, high lutein, lutein plus zeaxanthin
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Peking University